Background {#Sec1}
==========

Increased concentrations of circulating lipid profiles are a strong risk factor for cardiovascular disease \[[@CR1]\]; high concentrations of total-, LDL-cholesterol, or triglycerides, as well as, low concentrations of HDL-cholesterol are consistently correlated with incidence of cardiovascular diseases (CVDs) \[[@CR2], [@CR3]\]. Metabolic syndrome (MetS) is considered as an insulin resistant syndrome comprising impaired glucose tolerance, decreased insulin sensitivity, dyslipidemia, central obesity, and hypertension, all of which are well- established risk factors for CVDs \[[@CR4]\]. In addition, MetS is correlated with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), colorectal disease, atrial fibrillation and hypothyroidism \[[@CR5], [@CR6]\]. NAFLD is also associated with impaired liver enzymes, including, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), dysfunctional fat cells, and adipose tissue insulin resistance, resulting in hyperglycemia and dyslipidemia \[[@CR7], [@CR8]\].

The beneficial effects of resveratrol, plant sterols, and stanols on lipid profiles and modifying cardiovascular risk factors have been reported \[[@CR9]--[@CR13]\]. Resveratrol is a natural polyphenolic compound found mainly in peanuts and in the skin of red grapes that is used as a dietary supplement to improve metabolic profiles \[[@CR14]\]. The effects of resveratrol supplementation on lipid profiles and liver enzymes have already been evaluated; however, these findings are controversial. In a meta-analysis on seven randomized controlled trials (RCTs), conducted by Sahebkar et al. \[[@CR15]\], resveratrol supplementation had no effect on lipid profile. In another meta-analysis conducted by Hausenblas et al. \[[@CR16]\], resveratrol supplementation to patients with T2DM was more effective on the systolic blood pressure, hemoglobin A1c, and creatinine, but did not affect fasting glucose, insulin resistance, diastolic blood pressure, insulin, triglycerides, LDL-and HDL-cholesterol concentrations. However, another meta-analysis of then RCTs showed no effects of resveratrol supplementation on total-, LDL-cholesterol, triglycerides, and fasting glucose concentrations \[[@CR17]\]. Differences in study design, study population's characteristics, the dosage of resveratrol used, and the duration of intervention might explain the discrepancies among different studies.

We aimed to systematically review the trials investigating the effect of resveratrol supplementation on lipid profiles and liver enzymes and to summarize the impact among patients with MetS and related disorders.

Methods {#Sec2}
=======

PRISMA guideline (ERF) (the preferred reporting items for systematic reviews and meta-analyses) was used to design and implement this meta-analysis.

Search strategy {#Sec3}
---------------

Two independent authors (MA and OT) performed a comprehensive search to identify the relevant RCTs through inception up to November 2018. Online databases, including Cochrane Library, PubMed, Embase, and Web of Science databases by using the following MeSH and text keywords: patients \["Mets" OR "NAFLD" OR "disorders related to MetS" OR "diabetes" OR "T1DM" OR "T2DM" OR "overweight" OR "obese" OR "chronic kidney disease" OR "hypertension" OR "high blood pressure" OR "dyslipidemia" OR "CVD"\], intervention ("resveratrols" OR "resveratrol" AND "use" OR "supplementation" OR "intake"), and outcomes lipid profiles \["triglycerides" OR "total cholesterol" OR "LDL-cholesterol (LDL-C)" OR "HDL-cholesterol (HDL-C)"\] and liver measurements \["alanine aminotransferase (ALT)" OR "aspartate aminotransferase (AST)" OR "gamma-glutamyl transferase (GGT)"\]. Clinical trials retrieved that estimated the effect of resveratrol intake on lipid profiles and/or liver enzymes. Our search strategy was limited to human RCTs published in English language. We conducted a manual search in the reference list's included articles and pervious relevant reviews to find other additional articles.

Selection criteria {#Sec4}
------------------

The following inclusion criteria were used to select the related articles: RCTs were among humans (with parallel or cross-over design) with metabolic diseases, administrated resveratrol supplements in the intervention group and received placebo in the comparison group, contained sufficient data on mean changes of lipid profiles (including, triglycerides, total-, LDL-, and HDL-cholesterol concentrations), and liver enzymes (ALT, AST, and GGT concentrations), along with standard deviation (SD) or related 95% confidence intervals (CIs) at the baseline and at the end of trial for the intervention and placebo groups. RCTs which were not placebo controlled or other type of studies including animal, in vitro, case report, and case series, also abstracts or protocols without full texts, and studies with dosage of resveratrol lower than 20 mg/day were excluded.

Data extraction {#Sec5}
---------------

Two independent investigators (MA and OT) extracted data using a standard Excel forms according to the following items: first author's name, publication year, country, demographic characteristics of participants, study methods, sample size (intervention/placebo groups), dose of treatment, type of intervention, type of diseases, the mean ± (SD) of changes for triglycerides, total-, LDL-, HDL-cholesterol, ALT, AST, and GGT concentrations in the intervention and placebo groups at the baseline and at the end of intervention. If the outcomes were reported by different doses, types of supplements, or duration of the intervention, we treated each situation as a separate study. Disagreements were resolved by discussion with a third author (ZA).

Quality assessment {#Sec6}
------------------

The Cochrane Collaboration risk of bias tool was applied to assess the quality of selected RCTs using the following domains: "randomization generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data and selective outcome reporting, and the other sources of bias".

Statistical analysis {#Sec7}
--------------------

All statistical analyses were conducted using STATA software version 12.0 (Stata Corp., College Station, TX) and RevMan V.5.3 software (Cochrane Collaboration, Oxford, UK). Weighted mean differences (WMDs) and 95% CIs were considered as the overall combined effect sizes. Heterogeneity across included trials was examined using the Cochrane's Q and I^2^ statistics. I^2^ \> 50% with *P* \< 0.05 indicated that a significant heterogeneity exists, therefore, the DerSimonian and Laird random effects model were used to combine effect sizes; otherwise, the inverse variance fixed-effect model was applied. Sensitivity analyses were performed to evaluate the impact of each included clinical trials on the validity of the overall combined WMDs. Subgroup analyses were conducted to examine the source of heterogeneity according to the following possible moderator variables; type of interventions (resveratrol plus other nutrients or drugs vs. resveratrol alone), dosage of resveratrol (\> 250 vs. ≤250 mg/day), duration of intervention (≤8 vs. \> 8 weeks), and type of chronic condition (e.g. overweight, or obese, or other chronic diseases vs. T2DM). The potential evidence of publication bias was determined using Egger's- and Begg's-test. *P*-value less than 0.05 were considered as statistically significant.

Results {#Sec8}
=======

In initial online database searches, 2459 reports were identified. After removing duplicates citations by reviewing titles and abstracts and excluding the irrelevant citations, 31 studies (35 effect sizes) were finally included. Figure [1](#Fig1){ref-type="fig"} shows the stepwise with more details of the identification and selection of the relevant articles. All 35 included effect sizes were randomized, placebo-controlled trial. Twenty-nine studies were conducted using parallel design and six studies had cross-over design. The total number of the participants among included studies was 1722 individuals (890 persons in the resveratrol group; and 832 in the placebo group). Thirty-two studies calculated the influences of resveratrol intake on triglycerides, twenty-eighth on total cholesterol, twenty-seven on LDL-cholesterol, twenty-nine on HDL-cholesterol, thirteen on ALT, ten on AST, and five studies on GGT concentrations. The duration of resveratrol supplements ranged from four to 48 weeks and dosage of the intervention varied from 20 to 3000 mg/day among included articles. Table [1](#Tab1){ref-type="table"} illustrates the characteristics of the included articles. The quality assessment of included articles performed by authors' judgment according to each bias item is presented in Fig. [2](#Fig2){ref-type="fig"}**.**Fig. 1Literature search and review flowchart for selection of studiesTable 1Characteristics of included studiesAuthors (Ref)Publication yearSample size (control/intervention)Population/CountryIntervention (name and daily dose)DurationPresented dataAge (y) (control, intervention)Arzola-Paniagua ~(a)~ et al. \[[@CR18]\]201624/15Obesity/MexicoResveratrlol 300 mg24 weeksTG33.7 ± 11.9, 38.8 ± 9.59Arzola-Paniagua ~(b)~ et al. \[[@CR18]\]201621/24Obesity/MexicoResveratrlol 300 mg24 weeksTG40.96 ± 10.0, 39.76 ± 8.91Bashmakov YK et al. \[[@CR19]\]201410/14T2DM/EgyptResveratrol 100 mg2 monthsHDL-C, LDL-C, and TC54 ± 10.1, 59.8 ± 6.6Bhatt JK et al. \[[@CR20]\]201229/28T2DM/IndiaResveratrol 250 mg3 monthsTG, HDL-C, LDL-C, and TC56.67 ± 8.91, 57.75 ± 8.71Goh KP et al. \[[@CR21]\]20145/5T2DM/SingaporeResveratrol 3000 mg12 weeksTG, HDL-C, LDL-C, and ALT55.8 ± 7.3, 56.8 ± 5.3Imamura H et al. \[[@CR22]\]201725/25T2DM/JapanResveratrol 100 mg12 weeksTG, HDL-C, TC57.4 ± 10.6, 58.2 ± 10.1Zare Javid A et al. \[[@CR23]\]201722/21T2DM/IranResveratrol 480 mg4 weeksTG49.1 ± 7.4, 50.9 ± 8.9Kjær TN et al. \[[@CR24]\] ~(a)~201712/21MetS/DenmarkResveratrol 150 mg16 weeksTG, HDL-C, LDL-C, TC, and ALT49.1 ± 6.69, 47.8 ± 6.36Kjær TN et al. \[[@CR24]\] ~(b)~201712/21MetS/DenmarkResveratrol 1000 mg16 weeksTG, HDL-C, LDL-C, TC, and ALT51.9 ± 5.86, 47.8 ± 6.36Kumar BJ et al. \[[@CR25]\]201329/28T2DM/IndiaResveratrol 250 mg6 monthsTG, HDL-C, LDL-C, and TC56.67 ± 8.91, 57.75 ± 8.71Militaru C et al. \[[@CR26]\] ~(a)~201329/29Stable angina/RomaniaResveratrol 20 mg2 monthsTG, HDL-C, LDL-C, and TC64.9 ± 5.8, 64.2 ± 7.1Militaru C et al. \[[@CR26]\] ~(b)~201329/29Stable angina/RomaniaResveratrol 20 mg2 monthsTG, HDL-C, LDL-C, and TC66.3 ± 5.5, 63.7 ± 6.2Most J et al. \[[@CR27]\]201620/18Obese/NetherlandsResveratrol 80 mg + 282 mg epigallocatechin-3-gallate12 weeksTG, HDL-C, LDL-C, and TC36.1 ± 9.33, 38.7 ± 9.83Movahed A et al. \[[@CR28]\]201331/33T2DM/IranResveratrol 1000 mg45 daysTG, HDL-C, LDL-C, TC, ALT,AST, and GGT52.45 ± 6.18, 51.81 ± 6.99Poulsen MM et al. \[[@CR29]\]201312/12Obese/ DenmarkResveratrol 1500 mg4 weeksTG, HDL-C, LDL-C, TC, and ALT44.7 ± 12.12, 31.9 ± 10.03Seyyedebrahimi S et al. \[[@CR30]\]201823/23T2DM/ IranResveratrol 800 mg2 monthsTG, HDL-C, LDL-C, TC, ALT, and AST54.96 ± 6.37, 58.72 ± 6.06Méndez-del Villar M et al. \[[@CR31]\]201410/11MetS/ MexicoResveratrol 1500 mg3 monthsTG, HDL-C, LDL-C, and TC39.8 ± 5.4, 40.3 ± 5.4Witte AV et al. \[[@CR32]\]201423/23Overweight subjects/GermanyResveratrol 200 mg26 weeksTG and TC64.8 ± 6.8, 63.7 ± 5.3Chachay VS et al. \[[@CR33]\]201410/10NAFLD/AustraliaResveratrol 3000 mg8 weeksTG, HDL-C, LDL-C, TC, ALT, and AST48.8 ± 12.2, 47.5 ± 11.2Chen S et al. \[[@CR34]\]201530/30NAFLD/ChinaResveratrol 300 mg12 weeksTG, HDL-C, LDL-C, TC, ALT, AST, and GGT45.2 ± 10.0, 43.5 ± 11.0Faghihzadeh F et al. \[[@CR35]\]201525/25NAFLD/IranResveratrol 500 mg12 weeksTG, HDL-C, LDL-C, TC, ALT, AST, and GGT44.04 ± 10.10, 46.28 ± 9.52Kantartzis K et al. \[[@CR36]\]201852/53Overweight and insulin resistant Subjects/GermanyResveratrol 150 mg12 weeksTG, HDL-C, LDL-C, TC, ALT, AST, and GGT18--70Most J et al. \[[@CR37]\]201814/11Obesity/NetherlandsResveratrol 80 mg + 282 mg epigallocatechin-3-gallate12 weeksTG36 ± 3, 40 ± 3Khodabandehloo H et al. \[[@CR38]\]201820/25T2DM/IranResveratrol 800 mg/day8 weeksTG, HDL-C, LDL-C, TC, ALT, and AST56.48 ± 6.72, 61.10 ± 5.61Chekalina NL et al. \[[@CR39]\]201633/30CAD/UkraineResveratrol 100 mg2 monthsTG, HDL-C, LDL-C, and TC48--72Fujitaka K et al. \[[@CR40]\]201117/17MetS/JapanTrans resveratrol 100 mg (Longevinex)3 monthsTG, HDL-C, and LDL-C63 ± 9,62 ± 14Cicero AF et al. \[[@CR41]\]20160verall 25Hypercholesterolemic/ItalyResveratrol 20 mg and monacolins from *M. purpureus*10 mg4 weeksTG, HDL-C, LDL-C, TC, ALT, and AST18--70Biesinger S et al. \[[@CR42]\]2016Overall 18Hypertension/USAResveratrol 60 mg4 weeksTG, HDL-C, LDL-C, and TC44 ± 3Timmers S et al. \[[@CR43]\]2011Overall 11Obesity/NetherlandsResveratrol 150 mg30 daysTG52.5 ± 6.95, 52.5 ± 6.95van der Made SM et al. \[[@CR44]\]2015Overall 45Obesity/NetherlandsResveratrol 150 mg4 weeksHDL-C and TC61 ± 7de light M et al. \[[@CR45]\]2018Overall 13T2DM/NetherlandsResveratrol 150 mg30 daysHDL-C, LDL-C, TC, AST, and GGT66 ± 7.7Simental-Mendía LE et al. \[[@CR46]\]201931/31Dyslipidemia/MéxicoResveratrol 100 mg8 weeksTG, HDL-C, LDL-C, and TC20--65Fodor K et al. \[[@CR47]\]~(a)~201846/81Stroke/RomaniaResveratrol 100 mg + Allopathic treatment + physical rehabilitation48 weeksTG, HDL-C, LDL-C, and TC65.03 ± 8.24, 64.78 ± 6.32Fodor K et al. \[[@CR47]\]~(b)~201846/55Stroke/RomaniaResveratrol 200 mg + Allopathic treatment + physical rehabilitation48 weeksTG, HDL-C, LDL-C, and TC64.52 ± 8.05, 64.78 ± 6.32Mazza A et al. \[[@CR48]\]201830/30Hypertensive and hypercholesterolemic subjects/ItalyNutraceutical compounds capsule containing resveratrol 20 mg + standardized Mediterranean diet4 weeksTG, HDL-C, LDL-C, TC, ALT, and AST51.5 ± 7.8, 53.0 ± 8.1*CAD* Coronary artery disease, *MetS* Metabolic syndrome, *NAFLD* Non-alcoholic fatty liver disease, *NR* Not reported, *T2DM* Type 2 diabetes mellitus, *LDL-C* Low-density lipoprotein-cholesterol, *HDL-C* High-density lipoprotein-cholesterol, *ALT* Alanine aminotransferase, *AST* Aspartate aminotransferase, *GGT* Gamma-glutamyl transferaseFig. 2The summary of review authors' judgments about each risk of bias item for each included study

Main outcomes {#Sec9}
-------------

### Effects of resveratrol supplementation on lipid profiles and liver enzymes {#Sec10}

The impact of resveratrol supplementation on lipid profiles and liver enzymes are indicated in Fig. [3](#Fig3){ref-type="fig"}. The combined findings, using random-effects model showed that resveratrol intake significantly decreased total cholesterol (= − 7.65 mg/dL; 95% CI, − 12.93, − 2.37; *P* \< 0.01; I^2^: 83.4%) and increased GGT concentrations (WMD = 1.76 U/l; 95% CI, 0.58, 2.94; *P* \< 0.01; I^2^: 20.1%). We found no significant effect of resveratrol intake on triglycerides (WMD = -5.84 mg/dL; 95% CI, − 12.68, 1.00; *P* = 0.09; I^2^: 66.8%), LDL- (WMD = -2.90 mg/dL; 95% CI, − 10.88, 5.09; *P* = 0.47; I^2^: 96.0%), HDL-cholesterol (WMD = 0.49 mg/dL; 95% CI, − 0.80, 1.78; *P* = 0.45; I^2^: 74.0%), ALT (WMD = -0.14 U/l; 95% CI, − 3.69, 3.41; *P* = 0.93; I^2^: 79.6%), and AST (WMD = -0.34 U/l; 95% CI, − 2.94, 2.27; *P* = 0.80; I^2^: 88.0%) concentrations. Fig. 3A-G Meta-analysis standardized mean differences estimates for (**a**) triglycerides (**b**) for total-, (**c**) for LDL-, (**d**) for HDL-cholesterol, (**e**) for ALT, (**f**) for AST, and (**g**) for GGT concentrations in the resveratrol and control groups (CI = 95%)

### Subgroup analyses {#Sec11}

The findings of subgroup analyses indicated that there were no significant changes between before and after subgroup analyses combined WMDs for lipid profiles and liver enzymes. The results of subgroup analyses are indicated in Table [2](#Tab2){ref-type="table"}. Table 2The association between resveratrol intake on lipid profiles and liver enzymes using subgroup analysisVariablesNumber of WMD includedSubgroupsPooled WMD (random effect)95% CII^2^ (%)Overall I^2^ (%)Triglycerides32Overall-5.84−12.68, 1.0066.866.8Type of intervention6Resveratrol plus other nutrients or drugs−8.81−13.67, − 3.960.026Resveratrol−5.06− 14.41, 4.2971.8Dosage of resveratrol (mg/day)10≥ 500 mg resveratrol1.43−7.84, 10.690.022\<  500 mg resveratrol−8.07−16.20, 0.0574.1Duration of study (week)14\<  12 weeks−4.93−19.17, 9.3170.818≥ 12 weeks−5.40−11.53, 0.7440.5Type of disease8Overweight or obese1.44−13.46, 16.340.016Other−5.41−15.72, 4.9174.18T2DM−8.06−21.30, 5.1758.4Total cholesterol28Overall−7.65−12.93, − 2.3783.483.4Type of intervention5Resveratrol plus other nutrients or drugs−18.10−27.80, −8.3980.523Resveratrol−4.02−10.53, 2.4984.4Dosage of resveratrol (mg/day)9≥ 500 mg resveratrol−2.47−13.62, 8.6764.319\<  500 mg resveratrol−10.07−15.81, −4.3384.2Duration of study (week)15\<  12 weeks−8.61−16.64, −0.5778.513≥ 12 weeks−5.29−14.06, 3.4987.6Type of disease5Overweight or obese1.93−5.65, 9.500.015Other−8.32−16.28, −0.3683.88T2DM−9.68−21.12, 1.7683.4LDL-cholesterol27Overall−2.90−10.88, 5.0996.096.0Type of intervention5Resveratrol plus other nutrients or drugs−17.61−29.20, −6.0192.222Resveratrol0.84−8.72, 10.3996.1Dosage of resveratrol (mg/day)10≥ 500 mg resveratrol5.47−9.90, 20.8493.817\<  500 mg resveratrol−9.89−15.45, −4.3386.2Duration of study (week)14\<  12 weeks−7.38−15.47, 0.7185.913≥ 12 weeks0.59−12.65, 13.8497.6Type of disease3Overweight or obese3.47−6.35, 13.290.016Other−2.94−14.71, 8.8297.08T2DM−5.10−16.01, 5.8088.1HDL-cholesterol29Overall0.49−0.80, 1.7874.074.0Type of intervention5Resveratrol plus other nutrients or drugs2.310.63, 3.9844.424Resveratrol−0.02−1.52, 1.4973.4Dosage of resveratrol (mg/day)10≥ 500 mg resveratrol0.55−2.21, 3.3278.219\<  500 mg resveratrol0.31−1.11, 1.7269.1Duration of study (week)15\<  12 weeks0.26−1.66, 2.1872.114≥ 12 weeks0.79− 0.92, 2.5071.1Type of disease4Overweight or obese−0.46−2.51, 1.590.016Other0.61−1.55, 2.7669.39T2DM0.63−1.43, 2.7074.3ALT13Overall−0.14−3.69, 3.4179.679.6Type of intervention2Resveratrol plus other nutrients or drugs2.00−1.56, 5.5625.211Resveratrol−0.74−4.88, 3.4178.9Dosage of resveratrol (mg/day)9≥ 500 mg resveratrol−1.77−6.37, 2.8480.84\<  500 mg resveratrol2.19−0.51, 4.890.0Duration of study (week)7\<  12 weeks1.52−0.39, 3.430.011≥ 12 weeks−2.01−8.09, 4.0878.2Type of disease2Overweight or obese1.34−5.36, 8.040.07Other−1.76−7.00, 3.4883.84T2DM1.75−1.43, 4.9227.3AST10Overall−0.34−2.94, 2.2788.088.0Type of intervention2Resveratrol plus other nutrients or drugs−2.22−11.24, 6.7993.78Resveratrol0.18−2.70, 3.0587.5Dosage of resveratrol (mg/day)6≥ 500 mg resveratrol0.28−3.78, 4.3584.14\<  500 mg resveratrol−0.83−4.42, 2.7687.5Duration of study (week)7\<  12 weeks0.96−1.92, 3.8479.13≥ 12 weeks−3.16−6.43, 0.1276.1Type of disease1Overweight or obese−0.12−3.54, 3.30--5Other−2.61−6.29, 1.0683.64T2DM1.230.30, 2.170.0GGT5Overall1.760.58, 2.9420.120.1Type of intervention--Resveratrol plus other nutrients or drugs------5Resveratrol1.760.58, 2.9420.1Dosage of resveratrol (mg/day)3≥ 500 mg resveratrol1.05−1.31, 3.4055.92\<  500 mg resveratrol2.000.63, 3.360.0Duration of study (week)2\<  12 weeks2.010.71, 3.320.03≥ 12 weeks0.60−2.17, 3.3752.2Type of disease1Overweight or obese1.74−8.78, 12.26--2Other0.52−2.35, 3.3975.82T2DM2.000.71, 3.320.0*ALT* Alanine aminotransferase, *AST* Aspartate aminotransferase, *GGT* Gamma-glutamyl transferase

### Sensitivity analyses {#Sec12}

Sensitivity analyses showed no significant changes between the pre- and post-sensitivity combined WMDs for triglycerides, HDL-cholesterol, ALT, AST, and GGT concentrations. We found that there were a significant effect between before and after sensitivity pooled WMD for total cholesterol after removing Bhatt et al. \[[@CR20]\] study (WMD -5.76; 95% CI, − 12.23, 0.70), and for LDL-cholesterol after removing Faghihzadeh et al. \[[@CR35]\] study (WMD -6.32; 95% CI, − 11.41, − 1.22) (Table [3](#Tab3){ref-type="table"}). Table 3The association between resveratrol intake and lipid profiles and liver enzymes using sensitivity analysesVariablesPre-sensitivity analysisUpper & lower of effect sizePost-sensitivity analysisNo. of studies includedPooled WMD (random effect)95% CIPooled WMD (random effect)95% CIExcluded studiesTriglycerides32−5.84−12.68, 1.00Upper−4.24−8.78, 0.29Simental-Mendía \[[@CR46]\]Lower−6.86−13.88, 0.15Faghihzadeh \[[@CR35]\]Total cholesterol28−7.65−12.93, −2.37Upper−5.76− 12.23, 0.70Bhatt \[[@CR20]\]Lower−9.00−14.11, −3.89Faghihzadeh \[[@CR35]\]LDL-cholesterol27− 2.90−10.88, 5.09Upper−1.49−9.36, 6.37Cicero \[[@CR41]\]Lower−6.32−11.41, − 1.22Faghihzadeh \[[@CR35]\]HDL-cholesterol290.49−0.80, 1.78Upper0.69−0.59, 1.99Kumar \[[@CR25]\]Lower0.17−1.04, 1.40Movahed \[[@CR28]\]ALT13− 0.14− 3.69, 3.41Upper− 0.33− 4.10, 3.42Kantartzis \[[@CR36]\]Lower− 0.69−4.35, 2.96Khodabandehloo \[[@CR38]\]AST10−0.34− 2.94, 2.27Upper0.42− 2.19, 3.03Mazza \[[@CR48]\]Lower−0.77−3.51, 1.96Seyyedebrahimi \[[@CR30]\]GGT51.760.58, 2.94Upper2.110.89, 3.34Chen \[[@CR34]\]Lower1.07−1.22, 3.37de Light M \[[@CR45]\]*ALT* Alanine aminotransferase, *AST* Aspartate aminotransferase, *GGT* Gamma-glutamyl transferase

### Publication bias and quality assessment {#Sec13}

Egger and Begg's tests indicated no significant effect of possible publication bias for meta-analyses calculating the influence of resveratrol intake on triglycerides (P Begg's test = 0.74, P Egger's test = 0.69), LDL-cholesterol (P~Bg~ = 0.07, P~Ee~ = 0.53), HDL-cholesterol (P~Bg~ = 0.88, P~Ee~ = 0.98), ALT (P~Bg~ = 0.39, P~Ee~ = 0.11), AST (P~Bg~ = 0.42, P~Ee~ = 0.90), and GGT concentrations (P~Bg~ = 0.14, P~Ee~ = 0.60). The authors found that there was a significant effect of the potential of publication bias for total-cholesterol (P~Bg~ = 0.17, P~Ee~ = 0.00). We applied non-parametric method (Duval and Tweedie) to calculate the findings of censored articles for total-cholesterol; however, pooled WMDs findings did not statistically significant change after using Duval and Tweedie test.

Discussion {#Sec14}
==========

The findings of current systematic review and meta-analysis showed that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations.

MetS and related disorders are characterized by changes in fatty acid metabolism, which finally results in decreased HDL-cholesterol, and increased LDL-cholesterol as well as, triglycerides concentrations. As dyslipidemia is a well-established risk factor for MetS, diabetes, and CVDs, circulating lipid profiles are routinely addressed by pharmacotherapy. We found that resveratrol supplementation among patients with MetS and related disorders significantly reduced total cholesterol, but did not affect triglycerides, LDL-, HDL-cholesterol concentrations. Previously, the effects of resveratrol on weight loss \[[@CR49]\] and biomarkers of inflammation and oxidative stress among patients with MetS \[[@CR50]\], and coenzyme Q10 on lipid profiles among patients diagnosed with coronary artery disease \[[@CR51]\] were assessed. In a study conducted by Simental-Mendia et al. \[[@CR46]\], resveratrol supplementation at a dosage of 100 mg/day for 8 weeks to individuals with dyslipidemia significantly decreased total cholesterol and triglycerides concentrations. In addition, taking resveratrol supplements at a dosage of 300 mg/day for 3 months by patients with non-alcoholic fatty liver disease significantly decreased total- and LDL-cholesterol concentrations \[[@CR34]\]. The supplementation of resveratrol plus D-chiro-inositol for 60 days among overweight pregnant woman with an increased fasting glucose significantly reduced total-, LDL-cholesterol, and triglycerides concentrations \[[@CR52]\]. However, in a meta-analysis conducted by Zhang et al. \[[@CR53]\], resveratrol supplementation significantly increased total- and LDL-cholesterol concentrations. In addition, another meta-analysis found no significant effects on lipid variables following the supplementation of resveratrol in patients with T2DM \[[@CR16]\]. The hypocholesterolemic effect of resveratrol may be mediated by its phenolic hydroxyls contain that lead to oxidation of the unsaturated fatty acids and decreasing circulating cholesterol \[[@CR54]\]. In addition to the beneficial effects of resveratrol on lipid metabolism, the anti-atherosclerotic activity of resveratrol involves enhanced activity of peroxisome proliferator-activated receptor α \[[@CR55]\], suppressing platelet aggregation \[[@CR56]\], reduced blood pressure \[[@CR43]\], and improvement of the endothelial activity \[[@CR57]\]. Therefore, it is expected that resveratrol administration among patients with MetS and related disorders exerts a potential cardioprotective impact.

The current meta-analysis demonstrated that taking resveratrol supplements by patients with MetS and related disorders was associated with a significant reduction in GGT, but did not affect ALT and AST concentrations. In a study by Asghari et al. \[[@CR58]\], resveratrol supplementation at a dosage of 600 mg/day for 12 weeks to patients with NAFLD did not modify liver enzymes and oxidative/anti-oxidative status. In addition, previous animal studies have claimed that resveratrol protects the liver against steatosis \[[@CR59]\] and decreases intracellular lipids in the liver \[[@CR60]\]. In another study, Heebøll et al. \[[@CR61]\] demonstrated no significant improvement in the intrahepatic lipid content and the circulating concentrations of liver enzymes following resveratrol supplementation at a dosage of 1500 mg/day for 6 months among patients with NAFLD. An 8-week resveratrol supplementation at a dosage of 3000 mg/day, not only failed to show any significant improvements in NAFLD features, but also significantly increased liver enzymes concentrations \[[@CR33]\]. Also, Faghihzadeh et al. \[[@CR62]\] demonstrated that 500 mg/day resveratrol supplementation for 3 months among people with NAFLD significantly improved liver steatosis and ALT concentrations. A similar study with 600 mg/day resveratrol also documented a significant improvement in liver enzymes concentrations without any changes in liver steatosis degree \[[@CR34]\]. These inconsistent findings could be related to the stage of disease, type of diseases, the method of measuring liver fat content, different dosage of resveratrol used, or baseline metabolic characteristics of the participants.

Conclusions {#Sec15}
===========

This meta-analysis demonstrated that resveratrol supplementation to the patients with MetS and related disorders significantly reduced total cholesterol and increased GGT concentrations, but did not affect triglycerides, LDL-, HDL-cholesterol, ALT, and AST concentrations. Therefore, resveratrol supplementation to patients with MetS and related disorders may have a potential cardio-protective effect through the reduction of total cholesterol and GGT concentrations.

ALT

:   Alanine aminotransferase

AST

:   Aspartate aminotransferase

CADs

:   Coronary artery diseases

GGT

:   Gamma-glutamyl transferase

HDL-C

:   High-density lipoprotein-cholesterol

LDL-C

:   Low-density lipoprotein-cholesterol

MetS

:   Metabolic syndrome

NAFLD

:   Non-alcoholic fatty liver disease

NR

:   Not reported

T2DM

:   Type 2 diabetes mellitus
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